Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its phase 2 pipeline for diabetic kidney disease (DKD).
QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, has been awarded Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) by the United States Food and Drug Administration (FDA).
Novo Nordisk recently acquired three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.
Silo Pharma’s dissolvable ketamine implant, initially targeting fibromyalgia and chronic pain, has seen success in early research.
Gilead Sciences has celebrated the opening of its new research site at the Business Park in Oxford with a ribbon-cutting event.